NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results [Yahoo! Finance]
Nanobiotix S.A. - ADSs (NBTX)
Company Research
Source: Yahoo! Finance
largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Clinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of sponsorship for NANORAY-312 Strengthened financial position through the closing of a non-dilutive royalty financing with HealthCare Royalty for up to $71 million and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3) Advanced the Curadigm Nanoprimer platform with four new patent applications filed, new in vivo data presentations, external collaboration momentum building, and the launch of Chemistry, Manufacturing, and Controls (CMC) activities to support both internal pipeline and external collaborations Cash runway extended into early 2028 with €52.8 million in cash and ca
Show less
Read more
Impact Snapshot
Event Time:
NBTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBTX alerts
High impacting Nanobiotix S.A. - ADSs news events
Weekly update
A roundup of the hottest topics
NBTX
News
- Nanobiotix (NBTX) had its price target raised by Guggenheim from $26.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Nanobiotix H2 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results [TheStreet.com]TheStreet.com
- Nanobiotix GAAP EPS of -€0.50, revenue of €29.6M [Seeking Alpha]Seeking Alpha
NBTX
Sec Filings
- 3/12/26 - Form 6-K
- 2/25/26 - Form 6-K
- NBTX's page on the SEC website